CEO Wayne Paterson is interviewed by 180 Markets

CEO Wayne Paterson interview with 180 Markets

Anteris Technologies (ASX:AVR) nabs $20M funding package

CEO W. Paterson discusses the new funding package and upcoming FDA activities

Anteris set the stage in 2020 to prepare for DurAVR™ THV to be implanted in humans in 2021

""

DurAVR™ selected as Best Innovation in Aortic Valve Therapy at PCR Valves eCourse 2020

DurAVR™ FIH was selected from PCRValves eCourse 2020 as Best Innovation.

Anteris presenting at the Switzer Small & Micro-Cap Conference

CEO Wayne Paterson provided a company overview and discussed the strategic direction of Anteris, followed by a brief Q&A session with investors. The event was hosted by Peter Switzer and attendees had the opportunity to hear from ASX-listed small & micro-cap companies across a range of different sectors.

Bioshares November 2020 Report

Positive Data from First Five Patients in 15 Patient Pilot Study

Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

CEO Wayne Paterson is interviewed by Proactive Investors

CEO Wayne Paterson is interviewed by 180 Markets

CEO Wayne Paterson is interviewed by 180 Markets

The New Daily Podcast by John Elder with Prof Leon Neethling & Wayne Paterson

Anteris an Australian company’s innovative bid to transform heart valve technology

DurAVR™ Key Opinion Leader Summary

DurAVR™ Key Opinion Leader Summary

TAVR Key Opinion Leader Symposium

Full Video & CEO Presentation Deck

Credit Suisse Research Note

U.S. Medical Supplies & Devices TAVR KOL Symposium: Insights on Durability and the Future of TAVR Credit Suisse Research Note